The author retraces the history of "biotechnology" and the successive stages of its application in veterinary sciences.
INTRODUCTION
During the past few decades there has been accelerated progress in the biological sciences. Such an acceleration is rare in biology, where discoveries are usually made, developed and applied more slowly than in other scientific disciplines.
This has resulted in a certain apprehension of the way in which this field of science directly affects our environment, even though certain new discoveries hold promise of unexpected progress.
The number and variety of discoveries relevant to the veterinary sciences place this field in the forefront of such progress. The responsibilities of veterinarians are considerable, because these discoveries have first to be tested in animals, whether in the form of products administered or feed given to them.
The purpose of this document is to review the biotechnological procedures currently used or under investigation throughout the world, and the ways in which such research and its applications can be regulated. This paper has been compiled from the references cited and from reports received by the Office International des Epizooties from the following countries: Australia, Austria, Brazil, Canada, Chile, Cyprus, Czechoslovakia, France, Federal Republic of Germany (six reports), German Democratic Republic, Italy, Republic of Korea, Netherlands, Norway, South Africa, Taiwan R.O.C., Turkey, United Kingdom, United States of America, Uruguay and USSR.
BIOTECHNOLOGICAL PROCEDURES
Before providing a list and definitions, it is necessary to clarify the term "biotechnological procedures" as applied to veterinary sciences. The widest definition covers all possible fields of application of biotechnology. A narrower definition, confined to the new biotechnology and arising from discoveries in molecular biology (also called "genetic engineering"), will be provided later.
For this paper, the term covers all procedures which result in the practical application of our knowledge of biology, microbiology and molecular biology, to enhancing the potential of animals or strengthening their resistance to adverse factors in their environment.
Such procedures are seldom derived from a single discipline or a single discovery, since they result from the simultaneous application of several of these discoveries to solving a particular problem.
There are three major stages in the development of biotechnological procedures.
Before the birth of microbiology and cellular biology
At this time, biotechnology was applied empirically (without detailed knowledge of its intimate mechanisms). Nevertheless, these applications, like subsequent developments, have done much to change the fate of humanity. The selection of species and breeds of animals (or the plants on which they feed), the fermentation of fruits, cereals, herbage and milk, and the production of vaccines based on "crude" virulent material provided the key to progress and success in animal husbandry for centuries.
After the discoveries in microbiology and cellular biology
During this stage the application of biotechnology to the protection of human and animal health multiplied, particularly after the discovery of vaccines, sera, antibiotics, sulphonamides and vitamins, and also in selection, crossbreeding and artificial insemination. All these applications were related to the global demographic explosion of the twentieth century.
However, man created nothing new in biology, and did no more than exploit the material already available in nature, selecting and improving it. Even as he utilised errors in transcription of the genetic code, the precise mechanism was still unknown. Spontaneous mutants of clones of plants, animals and micro-organisms were identified and made use of.
After the development of molecular biology
Further steps forward were made by understanding the genetic code, which "programmes" cells, bacteria and viruses, and by learning to extract and modify these coded messages and transfer them from one cell to another.
Such mastery of the intimate mechanisms of life gave rise to the concern that the creation of something which does not occur "naturally" could upset the existing equilibrium.
In the historical context, this concern need not be expressed in such dramatic terms, for the changes now being produced consciously have for a long time been produced empirically.
The biotechnological procedures currently employed in veterinary science (Appendix I) can be classified into three major groups:
Group 1: Procedures which make use of existing genotypes
The most appropriate genes are selected from the natural reservoir of genes occurring within reproductive cells for the purpose of:
-directly enhancing the potential of living organisms (e.g. resistance and productivity); -indirectly enhancing this potential by utilising the properties of cells, bacteria or viruses selected in the laboratory, to produce ferments, vaccines, antibiotics, etc.
These methods have been utilised, directly or indirectly, throughout the history of biotechnology as defined above. They include:
-Traditional selection (quantitative genetics) of breeds of animals improved by crossbreeding existing breeds, either by natural mating or by artificial insemination. The animals may become more productive or more resistant to an adverse environment or to pathogens. The selection is made from the external characteristics (phenotype) of breeding animals or their offspring, or from the inherited characteristics (genotype) identified by genetic markers.
-Development in vivo of embryos collected from selected dams and transferred to other, unselected dams.
-Selection of cells possessing certain properties (e.g. carriers of the male or female chromosome, antibody-secreting cells), of micro-organisms (producing antibiotics, enzymes or immunising antigens) and of viruses (for vaccine production, cell transformation and gene transfer).
-Identification, selection and/or reproduction in vivo (biosynthesis) or in vitro (chemical synthesis) of cells or cell units (e.g. proteins, peptides, amino acids) or their products (e.g. hormones, polyclonal antibodies, enzymes). An example is the recent identification of the complete sequence of casein from cow's milk in the Federal Republic of Germany. For definitions of technical terms see Appendix III.
Group 2: Procedures which modify existing genotypes or which create new combinations of genes
These methods are another step forward in the exploitation of biological potential, but in an artificial manner, either by inducing greater cellular variability or by bringing together genes from different sources that would not be naturally combined in a single organism. The aim of such manipulations is the same as before, to enhance directly or indirectly the potential of living organisms. Another objective is to create specific tools, such as monoclonal antibodies, which make it possible to conduct more precise manipulations.
The following procedures fall within this group: -Creation of new breeds of animals by artificially induced mutations.
-Modification of cells, bacteria or viruses by induced "mutagenesis", followed by selection of mutants possessing the desired properties (due, for instance, to the addition or deletion of genes).
-"Immortalisation" of lymphocytes deliberately infected with an oncogenic virus.
-Fusion of tumour cells (capable of indefinite reproduction) with a particular cell clone (lymphocyte) of the immune system. The "hybridomas" thus created are capable of secreting in vitro or in vivo unlimited quantities of monoclonal antibodies of a specificity restricted to a single antigenic determinant (epitope). Such monoclonal antibodies may in turn be used for selecting, by directed mutagenesis, bacteria or viruses resistant to neutralisation by such antibodies.
-Hybridisation of known DNA with complementary DNA to detect the presence of specific nucleotide sequences (of a gene or pathogen), hence to detect the encoded protein. This is called diagnosis by molecular probe, or nucleic acid probe.
Group 3: Procedures which create new genotypes by DNA manipulation
This is the latest step in human intervention in the genotype. It is also called "genetic engineering", "biomolecular engineering" and "DNA recombination", and is what many persons have in mind when speaking of biotechnology. It involves direct and specific manipulation of the genes. If the exact sequence of the amino acids which make up a particular protein is known, it is possible to isolate the gene encoding the protein. In other words, the coding DNA is localised by its complementary messenger RNA. The required genes are usually excised from the genome by using restriction enzymes which cut the DNA at a precise point. The use of other enzymes makes it possible to reintroduce the excised gene into a vector DNA molecule (plasmid or virus), which carries it so that it can be expressed in the host cell or micro-organism.
It is possible to create a new genome by deleting or by adding other genes. The genes may be transferred to another cell (eukaryote or prokaryote) or virus as vectors, by using a plasmid, for example. Such vectors express the amino acid sequences encoded by the incorporated DNA, as well as those encoded by their own DNA.
The following procedures fall within this group: -Transfer of foreign genes to animals. Such "chimeras" can be created by micro-injection of DNA into fertilised eggs in vivo, by transformation of embryonic cells cultured in vitro, or by incorporation of the desired gene into the genome of a carrier retrovirus, which then inserts it into the cell together with its own genes. It is possible not only to add genes but also to transfer genes capable of stopping the transcription of undesirable genes.
-Introduction into fodder plants of foreign genes which code for a particular property (e.g. production of a limiting amino acid, fixation of nitrogen from air, resistance to herbicides).
-Introduction of foreign genes into bacteria or viruses, which is the most advanced procedure at present. It is also the most controversial due to the risk involved in subsequent dissemination of these transformed micro-organisms. a) Introduction into bacteria (e.g. Escherichia coli) or yeast (e.g. Saccharomyces) of genes coding for production of a hormone (such as insulin), an antibiotic, an enzyme (such as cellulase) or an antiviral agent (such as interferon); b) Introduction into a virus (e.g. pox-, baculo-or retrovirus) of genes coding for production of specific, immunogenic peptide sequences, or some other foreign sequence.
General remark: The division of biotechnological procedures into groups 1, 2 and 3 is practical for explaining the different principles on which they are based, for distinguishing those which are really new from those which have been used for a long time, and for assessing the corresponding risks. However, this division is artificial to the extent that certain manipulations utilise the techniques of more than one group. Thus, DNA from a heat-sensitive virus could be extracted by using a group 1 technique, transferred to another virus (group 3 technique) and then detected by a molecular probe or a monoclonal antibody (group 2 technique).
UTILISATION OF BIOTECHNOLOGICAL PROCEDURES
The historical stages in the development of biotechnology, the major principles and the diversity of methods have been described. The utilisation of biotechnology for veterinary science can now be discussed.
The four major fields which biotechnology can serve are: health, genetics, reproduction and animal nutrition.
UTILISATION IN ANIMAL HEALTH
The procedures of biotechnology are potentially applicable to the diagnosis, prevention and treatment of diseases.
Diagnosis of diseases

Improvement of conventional techniques
The procedures have a wide range of sensitivity. For example, an infection of an animal can be detected with a very small amount of virus (i.e. viral antigen) or with certain specific nucleotides (i.e. nucleic acid probe). On the other hand, these procedures can be used to distinguish antibodies derived from infection from those derived from vaccination, to detect latent carriers of virus (as in Aleutian disease of mink, herpesvirus infections and pestivirus infections), and to form new, hybrid cell systems for virus isolation. Certain reports (South Africa) envisage that soon an entomologist in the field will be able to capture an insect, identify it immediately, discover which vertebrate it has fed upon, and which micro-organisms it is infected with.
Thus, biotechnology offers a more specific diagnosis (fewer false-positive results) than traditional methods, whether it is an antigen (of a parasite, bacterium or virus) or the corresponding antibody that is being tested for.
-Antigen can be detected by monoclonal antibodies, which are applied directly to the sample. A positive result, i.e. the presence of antigen, is revealed as radioactivity, fluorescence or some other label. Test strips of plastic or paper are available to detect certain antigens (immunoblotting), the result being revealed by a conjugated enzyme which colours a substrate. This is the enzyme-linked immunosorbent assay (ELISA) technique, which is rendered highly specific by the use of monoclonal antibodies.
Immunomagnetic particles can be coated with such antibodies to aid subsequent detection.
Test kits, in which either polyclonal antibodies (the "classical" ELISA) or monoclonal antibodies are used, have become widely available not just to veterinarians, but also to farmers. This can lead to problems, particularly when a notifiable disease is concerned.
Aready it is possible to test for certain diseases of cattle [enzootic bovine leukosis, foot and mouth disease (FMD)], horses (infectious equine anaemia), pigs (Aujeszky's disease), dogs (parvovirus infection, dirofilariasis), cat (feline leukaemia) and rabies occurring in all species (Appendix II). Monoclonal antibodies are being used not only to distinguish between field strains and vaccine strains of bacteria and viruses, but also to detect and titrate hormones (for example, progesterone) and chemical residues, such as antibiotics or pesticides.
-Monoclonal antibodies are being used increasingly to detect antibodies naturally occurring in blood or milk from animals in contact with a given antigen. This is done by "immunoblotting", a highly specific technique which purifies the antigen in situ so that it can attach to the antibody being tested for, or by a competitive technique between the antibody being tested for and a monoclonal antibody. The latter is useful for distinguishing infected animals from animals inoculated with a virus vaccine which does not contain all the viral antigens, for example, pigs vaccinated with an Aujeszky's disease virus which lacks the glycoproteins gX and gl.
Creation of new techniques
"Restriction maps" specific for each pathogen can be determined by digesting nucleic acids with various bacterial enzymes and then transferring them to nitrocellulose membranes (see the term "blot" in Appendix III). A similar technique can also be used for antigens.
The use of nucleic acid probes is the most promising development. Certain DNA probes can be used to detect otherwise undetectable amounts of a particular serological variety, as in the case of serovars of pathogenic leptospires. Other probes are being investigated for inter-specific diagnosis, which used to be laborious and imprecise, for example, differentiating species of Mycoplasma, Mycobacterium, Chlamydia and Brucella.
Probes are already available for rota-, corona-, swine fever, rinderpest and rabies viruses (see the list in Appendix II).
Their performance may be significantly enhanced by the polymerase chain reaction (PCR) technique which amplifies genes and facilitates detection, in particular by cold (i.e. non-radioactive) probes.
Prevention of disease
Disease prevention, an area of intensive research, poses the difficult problem of testing vaccines for safety and efficacy. However, it is one which offers the most promise in regard to the development of vaccines which cannot be produced by conventional procedures, such as those against helminths, protozoa, rickettsia and some bacteria and viruses. Many of these pathogens create insurmountable obstacles to raising livestock in tropical countries.
As in the preceding paragraph, a distinction can be made between improvements to existing techniques and the creation of new techniques.
Improvements to existing techniques
Apart from its usefulness in diagnosis and epidemiology, biotechnology can contribute to disease prevention in two ways:
-Natural immunity (resistance to disease): The selection of breeding animals found to be the most resistant to a disease from field trials or laboratory experiments is already being practised in some countries for certain protozoal diseases (e.g. trypanosomiasis) and viral diseases (e.g. scrapie). Such selection can be aided by tagging, e.g. with a nucleic acid probe, the resistance factors involved in certain infections. Currently under investigation is the absence of a cellular receptor for K88 antigen in pigs, the absence of complement factor C5a (favouring the development of listeriosis) and the gene for sensitivity to salmonellosis in sheep. The role of genes of the major histocompatibility complex (MHC) is being investigated in cattle (BoLA). Such genes may be involved in conferring resistance to theileriasis and enzootic bovine leukosis (bovine leukaemia). For poultry, research is oriented towards finding a link between MHC genes and autoimmune thyroiditis and Marek's disease. For the latter disease, the objective would be to introduce a resistance gene into the genome of breeding fowls.
Such progress is based upon knowledge of the molecular basis of resistance (or sensitivity) to diseases of animals. It may become possible to detect certain genetic shortcomings, such as a lack of uridine monophosphate synthetase in calves at birth. It may also one day be possible to transfer resistance genes from one species to another (e.g. transfer to pigs of a murine gene for resistance to influenza virus infection), and to "correct" faulty genes.
-Acquired immunity (vaccination): All the resources of biotechnology have been applied to improving vaccines.
The use of monoclonal antibodies as specific markers of attenuated vaccines or host mutants derived from multiplication in dysgenesic media, or in heterologous living organisms, e.g. lapinised swine fever virus, turkey herpesvirus against Marek's disease of fowls, rabies virus adapted to hamster cells for use in foxes.
-Labelling of vaccine strains in order to distinguish one from another (by deleting a non-essential antigen, for example), or to distinguish them from field strains.
-More reliable selection of vaccine strains obtained by mutation at precise antigenic sites, and identified by using monoclonal antibodies.
-Selection of variants more immunogenic and less pathogenic under specified conditions. Among the vaccines under study, emphasis should be given to vaccines derived from thermo-resistant or thermo-sensitive mutants of heat-sensitive strains, which multiply poorly at the core temperature of the vaccinated animal. Such mutants are selected empirically. Thus, a thermo-resistant mutant is used to vaccinate trout against rhabdoviral haemorrhagic septicaemia, and thermo-sensitive mutants are used to vaccinate against chlamydiosis, classical swine fever (hog cholera), Aujeszky's disease or rabies.
Creation of new techniques
Numerous entirely new techniques have been developed by using biotechnology in the two fields mentioned above.
"Natural" immunity: Research has been aimed at the direct transfer of resistance genes (e.g. against Marek's disease) or sequences corresponding to an antigen (e.g. of avian leukosis) into the genome. This would make it possible for the animal to become "naturally" resistant to a pathogen over successive generations.
Acquired immunity:
Major progress has been achieved in vaccine production, for example:
-Production of new types of non-replicating vaccines, incapable of multiplying within the body.
Many vaccines are being developed which consist of only a fragment of a virus, a synthetic peptide, which mimicks the immunogenic region of the virus. Examples are vaccines against bovine rotavirus, FMD virus and rabies virus. However, in many instances such fragments alone are capable solely of eliciting a primary immune response. In order for them to elicit a secondary response, they must be coupled to the surface of lipid vesicles (immunosomes) so that the immunogenic spatial configuration is reconstituted, or to bacteria or viruses (e.g. a rotavirus fragment associated with hepatitis B virus).
A nucleic acid fragment can also be inserted by genetic recombination (see below) into a vector which is then inactivated.
Finally, DNA fragments coding for the immunogenic fraction of a pathogen can be transferred to a non-pathogenic micro-organism, as was done in the case of non-pathogenic Escherichia coli carrying K88 antigen, used in the control of piglet enteritis.
Other techniques utilise antibodies produced by an animal immunised with a specific monoclonal antibody against the vaccine antigen. Such antibodies, called anti idiotypes, are the internal image of the primary antigen, and act as vaccines.
-Production of new types of replicative vaccines, capable of multiplying within the body.
Research has been based on two principles, the first of which is to modify the genome of a pathogen in order to render it harmless to the vaccinated animal. Usually this is done by eliminating certain genes, e.g. that coding for thymidine kinase, or proteins or peptides linked to virulence. The genes are eliminated by direct manipulation of the DNA, or by selection with monoclonal antibodies of modified pathogens which lack particular epitopes (e.g. in Aujeszky's disease and rabies).
The second principle is to insert the gene coding for the immunogenic fraction of the pathogen under study into a "vector", which may be a cell, bacterium (E. coli), yeast or virus (pox-, herpes-, adenovirus, etc.). There is currently much research on this type of vaccine, which makes it possible to envisage vaccination against diseases caused by helminths (e.g. schistosomes), protozoa (e.g. Babesia) and viruses (e.g. rabies, rinderpest). However, in most cases the vaccines are still at the experimental stage.
Treatment of disease
Biotechnology may make an important contribution to the treatment of diseases of animals in three fields: antibiotic therapy, passive immunisation and the use of interferons and lymphokines.
Antibiotic therapy: the application of biotechnology to obtain new antibiotics (particularly those which would not be inactivated by bacteria) has so far been confined to products for human use. On the other hand, veterinary science has benefitted already from a very useful task, facilitated by biotechnology: surveillance of the appearance of resistance to antibiotics in animals by detecting resistance markers in the bacteria. Plasmids, which consist of extrachromosomal DNA and which transfer resistance genes from one bacterium to another, can now be extracted and transferred by conjugation or transformation. By these manipulations, plasmids can be identified.
Passive immunisation: monoclonal antibodies, which are more specific than the polyclonal therapeutic immune sera so far available, are currently being examined for their efficacy and are being subjected to cost-benefit analysis (e.g. for treating enteritis in cattle, antihormones).
Interferons and lymphokines: interferons are proteins which induce antiviral resistance in the cell, while lymphokines (interleukins, cytokines) mediate the cellular immune response. These proteins have been studied mainly in laboratory animals with a view to their use in human beings.
New biotechnological procedures involving genetic recombination may make it possible to produce interferons and cytokines economically, which would facilitate their marketing for veterinary use. This has happened already with alpha-interferons (produced in E. coli), proposed for use in pigs, dogs, cattle and horses; gammainterferons (also produced in E. coli) proposed for use in pigs and cattle, and interleukin 2 (produced in a yeast) for use in cattle. However, as with other types of therapy, only time will tell if such products are more effective and cheaper than existing treatments.
UTILISATION IN GENETICS AND ANIMAL REPRODUCTION
Biotechnology is capable of contributing, directly or indirectly, to the selection of more productive animals.
Direct contribution of biotechnology to selection
By the simultaneous application of all biotechnological procedures, it is now theoretically possible to identify and choose genes transferable between animals, to clone these genes and to select the animals carrying them (transgenic strains), which can be used for breeding. It takes a long time to achieve this, and little attention has been paid to the transfer of valuable genes, such as the "culard" gene of cattle, the Boroola hyperprolificacy gene of sheep, a cysteine gene which promotes wool formation, and a gene controlling the synthesis of milk proteins suitable for cheese production.
By contrast, genes for resistance to disease are easier to transfer (see above).
Indirect contribution of biotechnology to genetic improvement and animal reproduction
Rapid developments have been achieved in various techniques, including: -Artifical insemination: it is often forgotten that artificial insemination, one of the oldest techniques used, was the first biotechnological method applied to improving the genetics of animals. In turn it has benefitted from the diffusion, in space and time, of this genetic improvement. Artificial insemination has already given rise to the birth of millions of "improved" animals throughout the world.
-Embryo transfer:
this technique has been widely adopted, with many thousands of bovine embryos being transferred each year. Transfer has advantages for genetic improvement, zootechnical speculation and protection of health. It has begun to be used in goats and sheep (doubling their productivity) and may soon be applied in pigs.
-Cloning: the principle is to conserve a bank of embryos until it is known which will develop, and therefore which are valuable. The desirable embryos are then activated, so as to obtain a specimen of an ideal embryo. In order to avoid subsequent risk of consanguinity, a rigorous programme on the national scale is required. Consequently, the use of this technique is envisaged only by a few countries and only during the next few years.
-Herd management techniques: perfecting sexual cycles, induced (multiple) ovulation, oestrus detection, pregnancy diagnosis, "immunological castration", and control of ovulation by immunisation against ovulation inhibitors. These techniques have not only been used experimentally but also have been put into practice in the field.
-Embryo sexing: by cytogenetic techniques using antibody against H.Y., by hybridisation in situ with a molecular probe specific for the Y-chromosome or by DNA amplification. Embryo sexing is already used in cattle. The technique is still restricted in use and is confronted with numerous obstacles for practical application.
-Spermatozoal sexing: this technique shows great theoretical advantages but remains in the experimental stage as yield is low and numerous unsolved problems remain.
-In vitro fertilisation: currently at the research stage in cattle, in vitro fertilisation will increase the number and variability of embryos obtained from cows. However, the various procedures (controlled ovulation, maturation of ova and spermatozoa, culture followed by embryo transfer) are complex and are far from being adopted on a large scale. The most difficult stage (in vitro culture of the embryo after the blastocyte stage) has only been achieved by a few teams around the world and the yield is still very low.
UTILISATION IN ANIMAL NUTRITION
Biotechnology can be applied at three levels to improve the nutrition of animals: fodder plants, the ruminai microflora which digests or predigests the plants, and physiological regulation of metabolism in the animal.
Fodder plants
Most agronomic applications of biotechnology have important consequences for veterinary science, although they are indirect in the case of animal nutrition. Current research could affect the quality of herbage or cereals consumed by domestic and wild herbivores. Such research may lead to obtaining, by selection and by genetic manipulation, improved plants, such as those that are resistant to diseases or herbicides, those that contain more essential amino acids, and those that are more digestible or more prolific.
Bacterial microflora and protozoal microfauna
These rumen micro-organisms digest or predigest animal feed. Research is in progress on improving silage (produced by anaerobic, lactic fermentation of forage) by applying biotechnology. Such research would involve, in particular, the selection of the most frequently used or studied flora, chemical additives and enzymes (cellulases).
The digestive tract ecosystem (particularly in the rumen) can be manipulated by adding fatty acids, antibiotics, protectors of protein degradation, inhibitors of methane formation or mineral buffers, or by eliminating protozoa, or by altering rumen bacteria by introducing into their genome DNA encoding a specific enzyme, such as cellulase. Only the last procedure is really new, but its practical application is encountering formidable obstacles.
Digestion or predigestion of cellulose or crude vegetable products by enzymes produced by biotechnology may make it possible to utilise agricultural by-products, particularly those produced in tropical zones.
Nutritional metabolism of the animal
Biotechnological procedures may make it possible to improve further the performance of animals by altering their metabolism. Metabolism can be controlled by various growth promoters, such as organic acids, microbial cells, "probiotics", antibiotics, and additives incorporated into Escherichia coli, which are administered orally, or steroids, beta-receptor agonists, somatotropin and other hormones (e.g. hypothalamic hormones), which are administered by the parenteral route.
While some of these substances can be produced by the techniques of genetic engineering, particularly by biosynthesis, which reduces their retail price, most are produced by the conventional means of culturing selected micro-organisms, or extracting active factors from the organs of slaughtered animals.
Most of the growth promoters are used in young cattle and pigs.
Anxiety about the extremely rapid development and widely ranging applications of biotechnology is being expressed in every country, whether the procedures themselves or only the products are being used. There has been much discussion and comment on the reasons for this concern. It arises either from inadequate information (for all secret work raises anxieties), from too much information (leading to cognitive stress), or from confusion over the terms used, for "biotechnology" covers a wide range of technical risks, "manipulation" is suspect, "recombination" is dubious and " engineering " frightening.
At an international meeting held in 1974, it was proposed that governments should be allowed to implement safeguards for genetic engineering, for the need to reassure the users of products of biotechnology had become obvious at national and international levels.
Control of biotechnological procedures is based on a number of general principles, used by governments to make their own decisions.
The principles of control
The first step is to evaluate the different potential risks, and then to determine the means suitable for preventing risk.
The different risks
Two main risks are associated with biotechnology. The first is that caused by the production or release of pathogens, oncogenic substances and toxic substances. A modified micro-organism, apparently innocuous, may acquire a characteristic dangerous for a given species of animal or plant. This danger may come from the organism itself, from its combination with another micro-organism, or from its metabolic products. The second risk involves ecological aspects. A species of animal, plant or micro-organism created by selection or genetic manipulation may undergo uncontrolled multiplication, upsetting the existing natural equilibrium.
Ways of preventing risks
There are two types of safeguards, technical and human.
Technical safeguards
Safeguards implemented at research laboratories would guarantee physical containment (premises of categories P1 to P4), and biological containment (classification of the risks of an escape from I to IV for live organisms manipulated in the laboratory). At the industrial level, safeguards can be instituted that would prohibit development beyond the pilot stage of organisms shown to possess an uncontrollable risk in laboratory testing, and ensure that further development takes place under adequate confinement.
In the field the territory where an organism is to be released can be isolated, as far as practicable, using natural or artificial barriers (island, enclosed field, etc.). Rigorous surveillance of the results of releasing organisms can be maintained and provision made for possible destruction of the released organism, including its complete eradication from the experimental area.
CONTROL OF BIOTECHNOLOGICAL PROCEDURES
Human safeguards
These measures consist of providing information to persons handling the products of biotechnology and to the general public, and training for persons engaged in production, utilisation, and surveillance.
A hierarchy of risks and common classification categories
In the USA and many other countries, special procedures have been instituted for controlling the products of biotechnology, adopting the following classification: -Category 1: inactivated recombinant DNA vaccines, bacterial extracts, bacterial toxoids, subunits of bacteria or viruses, monoclonal antibodies.
-Category 2: live micro-organisms modified by addition or deletion of one or more genes (markers).
-Category 3: vaccines consisting of live vectors which carry foreign genes coding for immunising antigens or adjuvants of immunity.
Categories 1 and 2 are often considered as a single category.
Most of the legislation stipulates that a product must pass through several stages of control, first in the laboratory, then at an enclosed experimental station and then in a pilot field trial, before it can be released.
Numerous products in Category 1 are at present authorised throughout the world, but fewer than ten of Category 2 and only one (recombinant rabies vaccine in Belgium) of Category 3 have so far been authorised for release.
Control organisations
National organisations
National control organisations vary from country to country, and come under the direction of various Ministries (Agriculture, Environment, Health, etc.). In most cases an existing control organisation is used, advised by a specialist committee (e.g. the Genetic Manipulations Advisory Committee of Australia, the Advisory Committee on Genetic Manipulation of the UK, the National Biotechnology Committee of Canada, the "Commission de Génie Biomoléculaire" of France, the "Zentral Kommission für biologische Sicherheit" of the Federal Republic of Germany). Most of these committees have adopted the appropriate updated or revised texts for new products, such as "Guidelines for work with rDNA" and "Procedures for planned release of rDNA" (Australia), Special Orders made under the Animal Health and Protection of Animals Acts (UK), "Animal Disease and Protection Act" and "Environment Protection Act" (Canada), and "Considérations sur la préparation et le contrôle des médicaments vétérinaires issus de la biotechnologie" (France).
However, some countries have not found it necessary to alter the existing regulations concerning biological products. In the USA, the Act of 1903 and the "Virus-Serum-Toxin Act" of 1913 are used, and in Australia the requirements are left to local Institutional Biosafety Committees, which alone are responsible for the safety of their products.
International organisations
National legislation is usually based on recommendations or rules produced by international organisations for surveillance, coordination and control, namely the Commission of the European Communities, European Pharmacopoeia, Food and Agriculture Organisation, Office International des Epizooties, Organisation for Economic Co-operation and Development and the World Health Organisation.
These organisations draw upon Expert Committees and Specialist Commissions to produce international resolutions and codes of practice. Accord between national and international positions is not always easy, but it is facilitated considerably by the fact that experts are often consulted by the relevant international organisations.
CONCLUSION
Most of the modern biotechnological procedures (genetic engineering) applicable to animal production, cells or micro-organisms are still confined to the laboratory. Most of the products are still at the stages of research, technical development or economic evaluation, except those employed for diagnosis.
The gap between the practical applications of biotechnology and the publicity surrounding its development can be explained as follows. The time required for the development of the products of biotechnology is often underevaluated, compared to that for conventional products and this has prejudiced their competitiveness. The controls are numerous, prolonged and costly both for the producer and for the national or international authority responsible for licensing the product. Finally, consumer resistance may discourage the producer, when there is a choice between conventional and new techniques of production.
The actual risks of biotechnology are, in fact, little known and difficult to comprehend.
The accumulation of advice, recommendations, instructions and committees, often conceals our inability to grasp the potential risks of biotechnology, and may reflect a desire to dilute the responsibility for licensing the products.
Are the controls too severe ? We know that aspirin and the BCG vaccine against tuberculosis, both of which have had enormous benefits, would not pass the scrutiny of a modern licensing authority. Are the controls too lax ? History provides examples of unforeseen biological imbalance after the uncontrolled introduction of new pathogens into a locality.
In fact, the final decision to authorise a product of biotechnology is often based not on exhaustive reviews, but on common sense (primum non nocere), tests already performed and evaluated, and a little fatalism ("we are all recombinants").
The future success of products licensed depends on two important limiting factors: the capacity for the product to be incorporated into the natural environment, which is governed by successful adaptation and its biological activity, and market forces which determine its commercial success, and consequently its adoption in daily veterinary practice.
Interleukins
A group of lymphokines (or cytokines), which are protein mediators of the immune system. Interleukin 1 is produced by macrophage and interleukin 2 by activated lymphocytes. Interleukin activates the various functions of the immune system.
Major histocompatibility complex (MHC)
A region of the genome coding for the antigens usually responsible for graft rejection. This region is implicated in various aspects of the immune response, including resistance to disease.
Monoclonal antibody
Immunoglobulin secreted by a single clone of B-lymphocytes of the immune system, directed against a precise antigenic site (epitope) of a parasite or micro-organism. For stable production of large amounts of antibody, the lymphocyte is fused (hybridised) with a myeloma cell. The resulting hybridoma produces unlimited amounts of the desired monoclonal antibody, either in vitro or in vivo in an animal inoculated with the hybridoma.
Nucleic acid probe (molecular probe)
A DNA fragment capable of locating complementary DNA in a mixture of other DNAs. It is also possible to use RNA probes (riboprobes). The probe is labelled radioactively or non-radioactively (i.e. cold probe), allowing attachment of the probe to its complementary target to be detected.
Plasmid
A DNA molecule, transferable from one cell or micro-organism to another, thereby acting as vector or genetic messenger for pieces of DNA which have been incorporated into it.
Polyclonal antibodies
A mixture of antibodies secreted naturally and simultaneously by several clones of lymphocytes within the body in response to the presence of a foreign antigen (parasite, micro-organism, etc).
Polymerase chain reaction (PCR)
A technique for amplifying a given sequence of DNA involving the use of a heat-resistant bacterial DNA polymerase (Taq). Repeated cycles of replication in which heat serves to denature the DNA, allowing new DNA synthesis to occur, result in an amplified product which may then be detected by a nucleic acid probe (see above).
Prokaryote
A cell in which the genetic material is found in the cytoplasm and not within a nucleus (e.g. bacteria; cf. eukaryote).
RNA
Ribonucleic acid consisting of the same A, G and C bases as DNA, but not T, which is replaced by U (uracil). DNA is transcribed into messenger RNA by the activity of the enzyme RNA polymerase.
Western blot
A technique similar to Southern blot in which the nucleic acid probe is replaced by a labelled antibody (specific for an unknown protein) or a labelled protein (specific for an unknown antibody). These probes reach their targets within a sample placed on a support after preliminary electrophoresis. * * *
